MedTrace Logo

Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer

NCT00429182 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2013-04-10

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn the relationship of high-dose chemotherapy (HDCT) and circulating tumor cells (CTCs) in controlling metastatic breast cancer. The study also will investigate the role of CTCs in breast cancer.

Conditions

  • Breast Cancer
  • Metastatic Breast Carcinoma
  • Invasive Breast Carcinoma

Interventions

DRUG

Carboplatin

Target Area Under the Curve (AUC) of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.

DRUG

Cyclophosphamide

1.5 gm/m\^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.

DRUG

Thiotepa

120 mg/m\^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.

PROCEDURE

Stem Cell Transplant

Stem Cell Transplant on Day 0.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Naoto Ueno, MD, PhD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00429182 on ClinicalTrials.gov